Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | ATM | Q13315 | 2/20 | 0.49 |
| ▸ | ACACB | O00763 | 3/20 | 0.48 |
| ▸ | TACR1 | P25103 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | FDPS | P14324 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17053683 | 1.00 | NLRP3 (0.59) | NLRP3ALDH1A1ATMACACBTACR1 | |
| SCHEMBL27502717 | 0.89 | TACR1 (0.52) | NLRP3ALDH1A1ACACBTACR1POLB | |
| SCHEMBL6749422 | 0.89 | TACR1 (0.52) | NLRP3ALDH1A1ACACBTACR1POLB | |
| SCHEMBL29166064 | 0.89 | NLRP3 (0.59) | NLRP3ALDH1A1ATMACACBTHRB | |
| SCHEMBL3781118 | 0.86 | GPR132 (0.55) | ACACBFDPSLMNAGPR132 | |
| SCHEMBL6192282 | 0.86 | GPR132 (0.55) | ACACBFDPSLMNAGPR132 | |
| SCHEMBL30801050 | 0.86 | GPR132 (0.55) | ACACBFDPSLMNAGPR132 | |
| SCHEMBL3781113 | 0.86 | GPR132 (0.55) | ACACBFDPSLMNAGPR132 | |
| SCHEMBL23093209 | 0.86 | NLRP3 (0.56) | NLRP3ALDH1A1ATMTHRBCYP2C9 | |
| SCHEMBL15180408 | 0.86 | NLRP3 (0.56) | NLRP3ALDH1A1ATMTHRBCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014040709-A1 | PYRIDOMYCIN BASED COMPOUNDS EXHIBITING AN ANTITUBERCULAR ACTIVITY | ETH ZURICH (CH) | 2014-03-20 | — | — | WO | disclosed |
| US-8067642-B2 | Chiral phosphorous compounds | Celtice Catalysts Limited, Nova UCD (IE) | 2011-11-29 | — | — | US | disclosed |
| US-20100168456-A1 | CHIRAL PHOSPHOROUS COMPOUNDS | CELTIC CATALYSTS LIMITED (IE) | 2010-07-01 | — | — | US | disclosed |
| US-7084250-B2 | Process for the preparation of acetyl-amidiniophenylalanyl-cyclohexylglycyl-pyridinioalaninamides | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-08-01 | — | — | US | disclosed |
| US-20040225109-A1 | Process for the preparation of acetyl-amidiniophenylalanyl-cyclohexylglycyl-pyridinioalaninamides | AVENTIS PHARMA DEUTSCHLAND GMBH | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168456-A1 | CHIRAL PHOSPHOROUS COMPOUNDS | RPP30, PLCB3, INPP5D | NLRP3 4148/4885ALDH1A1 4513/4885ATM 3673/4885 |
| US-20040225109-A1 | Process for the preparation of acetyl-amidiniophenylalanyl-cyclohexylglycyl-pyridinioalaninamides | SERPINC1, F12, F11 | NLRP3 2799/4885ALDH1A1 1537/4885ATM 1935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.